Synopsis
Build an accurate breast-cancer stage from examination, targeted imaging and definitive pathology, while distinguishing pretreatment clinical stage from postoperative pathological and response stage.
- TNM separates the primary tumour, regional lymph nodes and distant metastases. Anatomical stage and prognostic biology are related but answer different questions.
- Clinical stage uses examination, breast and axillary imaging, needle pathology and indicated systemic staging before treatment; it remains the baseline after neoadjuvant therapy.
- Pathological stage uses the resection and nodal specimens after primary surgery. After neoadjuvant treatment, the yp prefix records residual disease and response rather than erasing pretreatment burden.
Reasoning priorities
Define the index tumour, multifocality and contralateral abnormalities for local staging.
Mammography and ultrasound measurements must be correlated with examination and biopsy. MRI is selective when conventional extent is unclear or density or lobular histology creates a defined uncertainty.
Worked reasoning
A 52-year-old has a 38 mm invasive carcinoma on imaging, a suspicious axillary node and no distant symptoms before treatment.
- In this illustrative case, examination finds no skin or chest-wall involvement. Mammography and ultrasound agree on a 38 mm invasive target, while core biopsy confirms ER-positive, HER2-negative carcinoma and sampling proves metastasis in the suspicious ipsilateral axillary node. These findings establish the clinical T2 size category and regional disease before treatment; the nodal category is assigned from the full clinical assessment, not from a presumed surgical node count.
- The multidisciplinary team requests systemic staging because the proven regional burden could change the treatment plan. CECT shows no distant metastases, so the distant assessment is recorded clinically as cM0. The report identifies the source and date of each finding rather than using absence of symptoms alone as proof of absence of spread.
- After discussion of tumour biology, breast size, local-treatment feasibility and systemic options, the patient chooses the recommended primary-surgery pathway. Breast conservation and the planned axillary clearance are completed; the operative and specimen records retain the pretreatment imaging and biopsy evidence.
- Excision measures 35 mm of invasive carcinoma with clear radial margins. One of twelve axillary nodes contains a 4 mm deposit. The postoperative record therefore adds pT2 and pN1a to the existing clinical distant assessment; it does not invent pM0 or silently replace the original clinical record.
- At postoperative review, pathology, imaging and the node count are reconciled and the completed record is used to plan adjuvant treatment. The patient explains back that the clinical and pathological measurements describe different assessments, and that future treatment response would be recorded separately rather than erasing the baseline.